Terms: = Ovarian cancer AND PDGFRA, MGC74795, 5156, ENSG00000134853, PDGFR2, CD140A, Rhe-PDGFRA, CD140a, P16234 AND Treatment
7 results:
1. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
2. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
3. Integrative network analysis identifies potential targets and drugs for ovarian cancer.
Zhang T; Zhang L; Li F
BMC Med Genomics; 2020 Sep; 13(Suppl 9):132. PubMed ID: 32958005
[TBL] [Abstract] [Full Text] [Related]
4. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts.
Liu Y; Chanana P; Davila JI; Hou X; Zanfagnin V; McGehee CD; Goode EL; Polley EC; Haluska P; Weroha SJ; Wang C
Sci Rep; 2019 Apr; 9(1):6314. PubMed ID: 31004097
[TBL] [Abstract] [Full Text] [Related]
5. miR-140-5p inhibits ovarian cancer growth partially by repression of pdgfra.
Lan H; Chen W; He G; Yang S
Biomed Pharmacother; 2015 Oct; 75():117-22. PubMed ID: 26297547
[TBL] [Abstract] [Full Text] [Related]
6. Connecting prognostic ligand receptor signaling loops in advanced ovarian cancer.
Eng KH; Ruggeri C
PLoS One; 2014; 9(9):e107193. PubMed ID: 25244152
[TBL] [Abstract] [Full Text] [Related]
7. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract] [Full Text] [Related]
